Bristol Myers Squibb (CELG-RI) Raw Materials (2010 - 2013)
Bristol Myers Squibb (CELG-RI) posted quarterly Raw Materials of $338.0 million for Q1 2013, up 40.25% year-over-year from $241.0 million in Q1 2012, and up 24.72% quarter-over-quarter from $271.0 million in Q4 2012.
Bristol Myers Squibb (CELG-RI) Raw Materials (2010 - 2013) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Raw Materials for 4 consecutive years, with $338.0 million the latest figure, recorded in Q1 2013.
- In Q1 2013, Raw Materials rose 40.25% year-over-year to $338.0 million; the TTM figure through Mar 2013 stood at $338.0 million (up 40.25% YoY), while the FY2012 annual figure was $271.0 million, up 4.23% from the prior year.
- Raw Materials rose to $338.0 million in Q1 2013 per CELG-RI's latest filing, from $271.0 million in the prior quarter.
- Across five years, Raw Materials topped out at $357.0 million in Q2 2011 and bottomed at $199.0 million in Q4 2010.
- Historically, Raw Materials has averaged $264.8 million across 4 years, with a median of $261.5 million in 2011.
- On a YoY basis, Raw Materials climbed as much as 44.39% in 2012 and fell as far as 26.33% in 2012.
- Bristol Myers Squibb's Raw Materials stood at $199.0 million in 2010, then jumped by 30.65% to $260.0 million in 2011, then climbed by 4.23% to $271.0 million in 2012, then advanced by 24.72% to $338.0 million in 2013.
- Business Quant data shows CELG-RI's Raw Materials at $338.0 million in Q1 2013, $271.0 million in Q4 2012, and $296.0 million in Q3 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 654.37 Bn | 633.61 Bn | 17.26 Bn |
| 2 | AbbVie | 471.07 Bn | 464.50 Bn | 12.70 Bn |
| 3 | Merck | 378.82 Bn | 371.68 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.27 Bn | 295.58 Bn | 11.24 Bn |
| 5 | Astrazeneca | 259.11 Bn | 254.21 Bn | 12.86 Bn |
| 6 | Amgen | 237.62 Bn | 223.63 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 183.34 Bn | 180.16 Bn | 6.22 Bn |
| 8 | Pfizer | 161.05 Bn | 149.36 Bn | 10.94 Bn |
| 9 | Gsk | 106.03 Bn | 101.87 Bn | 8.24 Bn |
| 10 | Bristol Myers Squibb | 208.28 Mn | -10.86 Bn | 9.25 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2013 | 338.00 Mn |
| Dec 31, 2012 | 271.00 Mn |
| Sep 30, 2012 | 296.00 Mn |
| Jun 30, 2012 | 263.00 Mn |
| Mar 31, 2012 | 241.00 Mn |
| Dec 31, 2011 | 260.00 Mn |
| Sep 30, 2011 | 205.00 Mn |
| Jun 30, 2011 | 357.00 Mn |
| Mar 31, 2011 | 218.00 Mn |
| Dec 31, 2010 | 199.00 Mn |